SOURCE: Theravance Biopharma

Theravance Biopharma

October 30, 2014 16:20 ET

Theravance Biopharma, Inc. to Report Third Quarter 2014 Financial Results on November 6, 2014

SOUTH SAN FRANCISCO, CA--(Marketwired - Oct 30, 2014) -  Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its US operating subsidiary, Theravance Biopharma US, Inc., that it will release financial results for the period ended September 30, 2014, after the market close on Thursday, November 6, 2014.

An accompanying conference call will be held at 5:00 p.m. Eastern Standard Time. To participate in the live call by telephone, please dial (855) 296-9648 from the U.S., or (920) 663-6266 for international callers. Those interested in listening to the conference call live via webcast may do so by visiting [the Investor Relations section of Theravance Biopharma's website at www.theravance.com. A replay of the conference call will be available on Theravance Biopharma's website for 30 days. A telephone replay will also be available until November 13, 2014 by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers, and entering conference ID number 22728509.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas, including respiratory disease, bacterial infections, central nervous system (CNS)/pain, and gastrointestinal (GI) motility dysfunction.

Theravance Biopharma has one approved product, VIBATIV® (telavancin), which was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. In addition, the Company has an economic interest in future payments that may be made by GlaxoSmithKline plc (GSK) pursuant to its agreements with Theravance, Inc. relating to certain drug programs, including the combination of fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) (FF/UMEC/VI), the combination of the bifunctional muscarinic antagonist-beta2 agonist (MABA) GSK961081 ('081) and FF ('081/FF), and MABA monotherapy. By leveraging its proprietary insight of multivalency to drug discovery, the Company is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. Theravance Biopharma is a publicly-held corporation, with US headquarters located in South San Francisco, California, and trades on the NASDAQ Global Select Market under the symbol TBPH. For additional information, please visit www.theravance.com.

THERAVANCE, the Cross/Star logo, MEDICINES THAT MAKE A DIFFERENCE and VIBATIV are trademarks and/or registered trademarks of the Theravance Biopharma group of companies.

Contact Information